You Lu

738 total citations
22 papers, 338 citations indexed

About

You Lu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, You Lu has authored 22 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 2 papers in Surgery. Recurrent topics in You Lu's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (10 papers) and Colorectal Cancer Treatments and Studies (6 papers). You Lu is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (10 papers) and Colorectal Cancer Treatments and Studies (6 papers). You Lu collaborates with scholars based in China, United States and United Kingdom. You Lu's co-authors include Ying Cheng, Jianying Zhou, Jianxing He, Yiping Zhang, Chao Wang, Li Zhang, Jin-Ji Yang, Tingting Xu, Thanyanan Reungwetwattana and Caicun Zhou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

You Lu

20 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
You Lu China 9 298 251 59 46 34 22 338
T-E. Ciuleanu Romania 11 240 0.8× 266 1.1× 57 1.0× 46 1.0× 29 0.9× 47 345
J.C.-H. Yang Taiwan 5 281 0.9× 263 1.0× 94 1.6× 46 1.0× 18 0.5× 12 353
Larry Leon United States 8 232 0.8× 258 1.0× 36 0.6× 41 0.9× 28 0.8× 14 316
Domnita-Ileana Burcoveanu France 4 196 0.7× 169 0.7× 62 1.1× 42 0.9× 51 1.5× 8 278
E‐E Ke China 8 239 0.8× 200 0.8× 80 1.4× 51 1.1× 32 0.9× 12 315
Annalisa Guida Italy 11 246 0.8× 165 0.7× 108 1.8× 72 1.6× 61 1.8× 39 323
Diana Gernhardt United States 7 200 0.7× 248 1.0× 135 2.3× 56 1.2× 22 0.6× 8 338
Ilze Bāra United States 9 225 0.8× 260 1.0× 57 1.0× 38 0.8× 37 1.1× 22 365
H. Akamatsu Japan 4 279 0.9× 211 0.8× 68 1.2× 89 1.9× 19 0.6× 10 314
Michela Lia Italy 9 249 0.8× 147 0.6× 112 1.9× 70 1.5× 33 1.0× 15 328

Countries citing papers authored by You Lu

Since Specialization
Citations

This map shows the geographic impact of You Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by You Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites You Lu more than expected).

Fields of papers citing papers by You Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by You Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by You Lu. The network helps show where You Lu may publish in the future.

Co-authorship network of co-authors of You Lu

This figure shows the co-authorship network connecting the top 25 collaborators of You Lu. A scholar is included among the top collaborators of You Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with You Lu. You Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Yue, Pengfei Zhou, Hui Wang, et al.. (2025). Stimulator of Interferon Genes Agonist Synergistically Amplifies Programmed Cell Death Protein-1 Blockade and Radiation-Induced Systemic Antitumor Responses via Tumor Microenvironment Enrichment. International Journal of Radiation Oncology*Biology*Physics. 123(2). 536–549. 1 indexed citations
2.
Zhou, Lin, Jianguo Sun, Conghua Xie, et al.. (2025). Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH). International Journal of Radiation Oncology*Biology*Physics. 124(1). 164–173. 1 indexed citations
3.
Zhou, Caicun, You Lu, Sang‐We Kim, et al.. (2024). Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. JTO Clinical and Research Reports. 5(9). 100700–100700. 2 indexed citations
4.
5.
Tian, Tian, Yanying Li, Juan Li, et al.. (2024). Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis. Translational Lung Cancer Research. 13(4). 861–874. 9 indexed citations
6.
Qin, Yi, Yaling Long, Juan Li, et al.. (2023). Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study. Cancer Science. 114(6). 2552–2559. 6 indexed citations
7.
Zhou, Qing, Shun Lü, Yong Li, et al.. (2022). [Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib].. SHILAP Revista de lepidopterología. 25(8). 555–566. 3 indexed citations
8.
9.
Zhou, Xiaojuan, Hui Yang, Youling Gong, et al.. (2021). Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. Journal of Cancer Research and Clinical Oncology. 148(10). 2589–2598. 11 indexed citations
10.
Deng, Zhujun, Yun Qin, Yongmei Liu, Yan Zhang, & You Lu. (2020). Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. Clinical Lung Cancer. 22(1). e70–e83. 10 indexed citations
11.
Zhang, Wen, Yiping Zhang, Qiong Zhao, et al.. (2020). Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. Journal of Thoracic Disease. 12(3). 639–650. 7 indexed citations
12.
Zhou, Caicun, Sang-We Kim, Thanyanan Reungwetwattana, et al.. (2019). Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 7(5). 437–446. 186 indexed citations
13.
Zhou, C., Xiaofan Zhu, Yihua Sun, et al.. (2018). OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial. Journal of Thoracic Oncology. 13(10). S345–S345. 6 indexed citations
14.
Hu, Min, Yi‐Long Wu, Xuehua Zhu, et al.. (2018). Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. Journal of Clinical Oncology. 36(15_suppl). 9077–9077. 2 indexed citations
15.
Lu, You, Jianying Zhou, Chin‐Hee Chung, et al.. (2017). P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy. Journal of Thoracic Oncology. 12(1). S1167–S1167.
16.
Zhou, Jianying, You Lu, Chin‐Hee Chung, et al.. (2017). P3.02a-014 Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1169–S1169.
17.
Lü, Shun, Tony Mok, You Lu, et al.. (2016). Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 9058–9058. 12 indexed citations
18.
Meng, Xue, Jianhua Wang, Xindong Sun, et al.. (2013). Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail. Radiotherapy and Oncology. 109(2). 275–280. 24 indexed citations
19.
Lu, You, et al.. (2012). Treatment of Postblepharoplasty Lower Eyelid Malposition by Aptos Thread. Annals of Plastic Surgery. 71(1). 13–15. 4 indexed citations
20.
Wu, Yi‐Long, Hong Bu, Gang Cheng, et al.. (2012). Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011).. PubMed. 4(1). 88–101. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T-E. Ciuleanu Breakdown of academic impact, for papers by J.C.-H. Yang Breakdown of academic impact, for papers by Larry Leon Breakdown of academic impact, for papers by Domnita-Ileana Burcoveanu Breakdown of academic impact, for papers by E‐E Ke Breakdown of academic impact, for papers by Annalisa Guida Breakdown of academic impact, for papers by Diana Gernhardt Breakdown of academic impact, for papers by Ilze Bāra Breakdown of academic impact, for papers by H. Akamatsu Breakdown of academic impact, for papers by Michela Lia
Rankless by CCL
2026